Stocks in play: Resverlogix Corp.
Has entered into definitive transaction documents for the two-year extension of the Company's US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (and payment of accrued interest thereon), extending the maturity date to May 13, 2026. Resverlogix Corp. shares T.RVX are trading unchanged at $0.05.
Read:
Bill Gates' Nuclear Bet: Why North American Uranium Projects Are Key to Powering AI and Homes
Addressing AI's Energy Hunger: Solutions from Leading Data Center Developers
Quantum Computing and Cybersecurity: Preparing for the Future of AI
Tech Companies Leading the Charge in the Transformative AI Era
Exposing 'AI Washing': Real Tech Developers Making Authentic AI Contributions